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Abstract
Background: Polysaccharopeptide (PSP) from Coriolus versicolor (Yunzhi) is used as a supplementary cancer treatment 
in Asia. The present study aims to investigate whether PSP pre-treatment can increase the response of the human 
leukemia HL-60 cells to apoptosis induction by Camptothecin (CPT).
Methods: We used bivariate bromodeoxyuridine/propidium iodide (BrdUrd/PI) flow cytometry analysis to measure the 
relative movement (RM) of the BrdUrd positively labeled cells and DNA synthesis time (Ts) on the HL-60 cell line. We 
used annexin V/PI flow cytometry analysis to quantify the viable, necrotic and apoptotic cells. The expression of cyclin 
E and cyclin B1 was determined with annexin V/PI flow cytometry and western blotting. Human peripheral blood 
mononuclear cells were used to test the cytotoxicity of PSP and CPT.
Results: PSP reduced cellular proliferation; inhibited cells progression through both S and G2 phase, reduced 3H-
thymidine uptake and prolonged DNA synthesis time (Ts) in HL-60 cells. PSP-pretreated cells enhanced the cytotoxicity 
of CPT. The sensitivity of cells to the cytotoxic effects of CPT was seen to be the highest in the S-phase and to a small 
extent of the G2 phase of the cell cycle. On the other hand, no cell death (measured by annexin V/PI) was evident with 
the normal human peripheral blood mononuclear cells with treatment of either PSP or CPT.
Conclusion: The present study shows that PSP increases the sensitization of the HL-60 cells to undergo effective 
apoptotic cell death induced by CPT. The pattern of sensitivity of cancer cells is similar to that of HL-60 cells. PSP rapidly 
arrests and/or kills cells in S-phase and did not interfere with the anticancer action of CPT. PSP is a potential adjuvant to 
treat human leukemia as rapidly proliferating tumors is characterized by a high proportion of S-phase cells.
Background
The polysaccharopeptide (PSP) extract of the Chinese
medicinal mushroom Coriolus versicolor (Yunzhi) has
been used in Asia to treat cancer as well as to alleviate
weakness, improve immunological activities, appetite and
comfort for patients [1]. The strong immunomodulatory
effects of PSP such as elevation of IL-2, natural killer cell
activity and T-cell proliferation may be beneficial to
advanced cancer patients with depressed immunity [2,3].
PSP can be potentially used to treat cancer due to its abil-
ity to distinguish cancerous cells from normal cells [4-6].
However, concerns remain that the PSP extract may
diminish the effectiveness of chemotherapeutic regimens
because little is known about the PSP anti-tumor action
mechanism. Our recent studies showed that instead of
interfering with the anticancer actions of drugs PSP
potentiated the anticancer effects of doxorubicin and
etoposide in human leukemia cells [3] and human breast
cancer cells through interfering the S phase progression
and DNA synthesis [4]. As PSP synchronizes cells in S-
phase, we hypothesize in this study that PSP may serve as
a chemotherapeutic agent in combination therapy with
other S-phase targeted drugs such as Camptothecin
(CPT). CPT is a cytotoxic quinoline alkaloid isolated
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(Camptotheca, Xishu, Happy Tree), a native plant of
China. CPT kills cancer cells by interfering with the func-
tion of DNA topoisomerase I (TopI) during DNA replica-
tion in the S-phase [7,8]. Incubation of cells with CPT
stabilizes the TopI-DNA cleavable complexes, leading to
fragmentation of nuclear DNA [8]. The cell sensitivity to
cytotoxic effects of CPT was reported to reach the high-
est in the late S-phase and early G2 [9]. CPT demon-
strated remarkable anticancer activity in preliminary
clinical trials but also produced side effects such as leu-
copenia [10].
Using the S-phase synchronization strategy, the present
study tests the hypothesis that pre-exposing the human
myelogenous leukemia HL-60 cells to PSP increases cell
death at low concentrations.
Methods
Preparation of PSP extract
PSP (340 mg/capsule, Winsor Health Products Ltd, Hong
Kong) powder was dissolved in distilled water by boiling.
All water soluble fractions were collected, centrifuged
and freeze-dried for a dry power. PSP stock solutions of
10 mg/ml were prepared from the dry powder to be used
in all experiments.
Cell line and cell culture
HL-60 cells were routinely cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum.
Cells were cultured at 37°C in a humidified atmosphere
with 5% CO2. The cultures were supplied with fresh com-
plete medium and cell density was adjusted to 1 × 105
cells/ml per flask every three days to maintain asyn-
chronicity and exponential growth. Cell densities were
monitored to ensure that they did not exceed 1 × 106
cells/ml. In all experiments, cells were fed with fresh
complete medium a day before experiments. Human
peripheral blood (Buffy coat) obtained from healthy
donors (age ranged 20-40 years) was provided by the
Hong Kong Red Cross Blood Transfusion Service.
Human peripheral blood mononuclear cells (PBMCs)
were isolated with Ficoll-Paque density gradient centrifu-
gation (Pharmacia Biotech, Sweden). Briefly, the diluted
Buffy coat (1:1 with RPMI medium) was layered on the
Ficoll-Paque and centrifuged at 400 g for 30 minutes at
room temperature. The PBMCs were washed twice with
RPMI medium and then suspended in the RPMI medium.
A series of dilutions was prepared from the PSP stock
solution (10 mg/ml) in RPMI and incubated with the HL-
60 cells for 24, 48 and 72 hours, respectively. For combi-
nation treatment of PSP and CPT, the HL-60 cells were
first exposed to PSP (25 μg/ml) for 72 hours before being
exposed to CPT (1 μM) for five more hours. The PBMCs
were treated with PSP and CPT in the same manner.
Cell proliferation and [3H] thymidine uptake assay
Cell proliferation and cell size were determined every 24
hours with Beckman Coulter Multisizer (Beckman
Coulter Electronics Ltd, USA). Cell suspension was
diluted in 20 ml PBS and the mixture was analyzed with
the multisizer. Cell viability was evaluated with the Try-
pan Blue Exclusion test (Sigma, USA).
For [3H] thymidine uptake assay, HL-60 cells (1 × 104
per well) were pipetted onto a 96-well plate. After incuba-
tion with or without PSP, the cells were pulsed with 0.5
μCi/well of [3H] thymidine for six hours before harvest.
Incorporated radioactivity was counted in a liquid scintil-
lation counter (Beckman LS3000, Beckman, USA). Each
concentration was tested in quadruplicates and repeated
on three separate occasions.
BrdUrd/PI immunostaining analysis by flow cytometry
Bromodeoxuridine (BrdUrd) propidium iodide (PI) flow
cytometry was used to determine DNA synthesis time
(Ts) via measurement of the relative movement of the
BrdUrd labeled S-phase cells as previously described [11-
13]. Cells were pulsed with BrdUrd (10 μM) in the last 20
minutes of PSP incubation and were washed, re-sus-
pended in warm complete culture medium with or with-
out PSP and further incubated for one and six hours for
BrdUrd analysis. After incubation, the cells were washed
with PBS and fixed with ice-cold ethanol (75%w/v in
Milli-Q water) and the fixed samples were stored at -20°C
for further analysis. Fixative was removed by centrifuga-
tion and the cell pellets were washed with PBS. DNA was
partially denatured by incubation with 1 M HCl for 20
minutes at room temperature, after which the cells were
washed three times with PBS containing 0.05% Tween-20.
Cells were incubated with 100 μl of anti-BrdUrd mono-
clonal antibody (5 μg/ml; 1:100) for one hour and further
incubation with a FITC-conjugated goat anti-mouse IgG
antibody (100 μl; 1:40) in the dark for another 30 minutes.
The cells were stained with PI staining solution (50 μg/ml
PI, 10 μg/ml RNase, 0.01 M Tris and 10 mM NaCl) before
flow cytometric analysis. The amount of DNA distribu-
tion in the difference phases of the cell cycle was analyzed
with the use of the WinList (Version 1.04, Verity Software
House Inc., USA) and ModFit software (Version 5.11,
Verity Software House Inc., USA).
Relative movement (RM) and DNA synthesis time (Ts)
were calculated as previously described [6,11-15]:
where Flud(t), FG0/G1 and FG2/M are the mean PI fluores-
cence (DNA content) of the BrdUrd labeled undivided
population G0/G1 and G2/M at time t (hour) after BrdUrd
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movement values at time 0 and t (hour) respectively after
BrdUrd pulsing.
Quantification of apoptosis by annexin V/PI flow cytometry
Using the annexin V binding assay with the Apoptosis
Detection Kit (Trevigen Inc., USA) and flow cytometry,
we determined the apoptosis induction effect of CPT
with and without PSP treatment on both HL-60 cells and
human peripheral blood mononuclear cells. Cells (2 ×
105) after incubation with or without PSP and CPT were
harvested and centrifuged at 400 × g for five minutes to
remove the culture medium. Cell pellets were washed
with 3 ml PBS and re-suspended in 500 μl binding buffer.
After centrifugation and removal of the binding buffer,
100 μl of annexin V incubation reagent (10 μl 10 × bind-
ing buffer, 10 μl propidium iodide, 1 μl annexin V conju-
gate and 79 μl Milli-Q water) were added to each sample.
Samples were incubated for 15 minutes in the dark at
room temperature. Cell suspension was then diluted with
400 μl binding buffer and was analyzed with a Coulter's
Epic Elite flow cytometer (Beckman and Coulter Elec-
tronics Ltd, USA).
Bivariate analysis of cyclin E and cyclin B1 expression by 
flow cytometry
Cells were harvested into 15 ml centrifugation tubes. All
samples were washed twice with 10 ml PBS and centri-
fuged at 400 g for five minutes. Supernatant was removed
and cell pellets were fixed with ice-cold ethanol (75%w/v
in Milli-Q water). The fixed samples were stored at -20°C
for further analysis.
The fixed samples were washed with 10 ml PBS-BSA
(1%). The cells were incubated with 100 μl of anti-cyclin E
monoclonal antibody (5 μg/ml; 1:100) or anti-cyclin B1
monoclonal antibody (1 μg/ml; 1:100) for one hour.
Mouse monoclonal isotype controls at equivalent con-
centration were used instead of the anti-cyclin antibodies
for the background fluorescence check. After incubation,
the primary antibodies of the cells were washed twice
with PBS-BSA, labeled with FITC-conjugated goat anti-
mouse IgG antibody (100 μl; 1:40) and kept in the dark at
room temperature for one hour. The cells were stained
with PI solution before flow cytometric analysis.
Western blot analysis of the expression of cyclin E and 
cyclin B1
Cells were harvested and washed twice with ice-cold PBS
(45 ml) followed by centrifugation at 400 × g for five min-
utes. Cell pellet was re-suspended in lysis buffer (5 × 106
cells/100 μl) with HEPES (25 mM; pH7.5), NaCl (150
mM), EDTANa2 (1 mM), DTT (1 mM), Triton × 100 (1%)
and protease inhibitor cocktail. The suspension was then
frozen and thawed three times with cold methanol at -
80°C before it was placed in ice for further 30 minutes
and then centrifuged. After centrifuged at 14,000 × g for
30 minutes at 4°C, the suspension was collected and
stored at -80°C. Protein quantity was determined with
Bradford assay. Protein extracts were mixed with an equal
volume of 2× sample buffer (0.125 M Tris-HCl, 4% SDS,
20% v/v glycerol, 0.2 M DTT, 0.02% bromophenol blue,
pH6.8) and the mixture was heated in boiling water for
three minutes.
Equal amounts of total protein (20 μg) were subjected
to 12.5% SDS-PAGE followed by Western blotting onto a
PVDF membrane (GE Healthcare Life Sciences, USA).
Membranes were incubated with anti-cyclin E antibodies
and detected with the matching species specific second-
ary HRP-conjugated antibodies. Proteins were detected
with the ECL system (GE Healthcare Life Sciences, USA)
and the band intensity was measured with Quantity One
software (Bio-Rad, USA).
Statistical analysis
All data are presented as mean standard deviation (SD).
Statistical differences between the treatment and control
groups were determined by post-hoc Duncan's test with
SPSS statistical software for Windows, version 12·0 (SPSS
Inc., USA). Probability values (P) < 0.05 were considered
statistically significant.
Results
PSP reduced HL-60 cells proliferation and [3H] thymidine 
uptake
PSP reduced HL-60 cells proliferation in a dose- and
time-dependant manner (Figure 1). The average cell size
of the HL-60 cells increased as PSP doses increased. The
mean diameter of the cells increased 13.82% after 72
Figure 1 The dose and time effect of PSP on human leukemia HL-
60 cell proliferation. HL-60 cells were treated with various PSP con-
centrations (0-400 μg/ml) for 24, 48 and 72 hours. Cells proliferation 
was determined with cell densities analysis on the Multisizer. Values 
are expressed as mean (SD) (n = 4). * P < 0.001, vs. control.
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size increase may be due to: (1) increased DNA content,
(2) increased protein synthesis, (3) inhibition of cells divi-
sion or (4) all of these events. The [3H] thymidine incor-
poration in the HL-60 cells was reduced by 77.2%, 79.4%
and 84.7% for treatment times of 24, 48 and 72 hours
respectively (Figure 3), suggesting DNA synthesis was
reduced in cells exposed to PSP.
Cell cycle arrest induced by PSP in S and G2/M phase
Bivariate BrdUrd/DNA analysis was used to investigate
the effect of PSP on HL-60 cells. PSP induced accumula-
tion of cells in the S-phase and G2/M phases by 56.1% (P
< 0.001) and 44.9% (P < 0.001) respectively (Figure 4). The
high level of BrdUrd-labeled cells in the S-phase suggests
that PSP may cause some hyper-prolongation for DNA
synthesis. DNA Ts increased from 9.76 hours to 11.70
hours (P = 0.045) in PSP-treated cells as measured by rel-
ative movement (Figure 5).
Effect of CPT and PSP on the viability, necrosis and 
apoptosis HL-60 cells and PBMCs
With a S-phase synchronization strategy, we showed that
pre-treatment of low dose PSP (25 μg/ml) for 72 hours
was able to enhance the cytotoxicity of CPT (1 μM) to the
HL-60 cells. The total viable, necrosis and apoptosis cells
population were determined by annexin V/PI flow
cytometry analysis in HL-60 cells and PBMCs in two sep-
arate experiments. CPT increased apoptosis from 5.05%
to 48.65% (R4), whereas PSP treatment induced apoptosis
(7.45%) in the HL-60 cells (Figure 6). Moreover, pre-treat-
ment of HL-60 cells with PSP increased their sensitivity
to CPT-induced apoptosis, raising the sensitive cell popu-
lation from 48.65% (CPT alone) to 66.6% (PSP pre-treat-
ment). We also tested further whether the apoptotic
response of the PSP-treated HL-60 cells to CPT was lin-
ear with dose-dependent in a separate experiment. With
doses of CPT ranged from 0, 10, 100 and 1000 nM for
treatment of five hours, PSP pre-treated cells (25 μg/ml,
72 hours) were also enhanced the cytotoxicity of CPT
(100 nM) by 30.12% (Figure 7). In contrast to the HL-60
cells, the PBMCs were not affected by treatment of PSP
nor CPT alone, or with their combination (Table 1).
Change in cell cycle distribution of HL-60 cells with CPT 
treatment alone and with PSP pre-treatment
Cell cycle distribution of HL-60 cells with or without PSP
(25 μg/ml) pre-treatment differed after the addition of
CPT (1 μM) (Figure 8). After incubation, CPT alone
induced a 51.12% increase of the pre-G1 peak. Most of the
S-phase cells (36.41%) were removed and only 14.71% of
apoptotic cells were from the non-S-phase cells. On the
other hand, combination treatment of PSP with CPT
removed 50.42% of the S-phase cells. The remaining
22.74% of apoptotic cells were likely to be the non-S-
phase cells.
Effect of PSP, CPT and PSP pre-treatment with CPT on cyclin 
E and cyclin B1 expression in HL-60 cells
Cyclin E expression in the control HL-60 cells was the
highest at G0/G1, slowly declined at late S-phase and was
nearly undetectable at G2/M phase (Figure 9a). PSP treat-
ment for 72 hours increased the cyclin E level in G0/G1, S
and G2/M phases by 67.76% (P < 0.001), 163.46% (P <
0.001) and 93.91% (P < 0.001), respectively (Figure 9a and
Figure 2 Effect of PSP on the average size of HL-60 cells. HL-60 
cells were treated with various PSP concentrations (0-400 μg/ml) for 72 
hours. Average diameter of HL-60 cells was measured with the Multi-
sizer.
Figure 3 Effect of PSP on [3H] thymidine uptake by HL-60 cells. 
Cells were pulsed with [3H] thymidine (0.5 Ci/well) for six hours after 
treatment with or without PSP. Cells were harvested and counted at 24 
hour intervals. Values are expressed as mean (SD) (n = 4). * P < 0.001, vs. 
control.
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lation of cyclin E during PSP treatment (Figure 9c). After
five hours of CPT (1 μM) incubation, the average cyclin E
protein level in G0/G1, S and G2/M phase of the control
(without PSP pre-treatment) was enhanced by 33.74%,
67.60% and 138.50% respectively (Figure 9a) while the
average cyclin E protein level in the PSP pre-treatment
group was not significantly changed. An increased pro-
portion of pre-G1 cells expressing cyclin E suggested that
Figure 4 Effect of PSP on HL-60 cell cycle distribution. HL-60 cells were treated with PSP (25 μg/ml) for 72 hours. Cell cycle distribution in G0/G1, S 
and G2/M phases was measured by DNA/PI flow cytometry. Values are expressed as mean (SD) (n = 5). * P < 0.001, vs. control.
Figure 5 Bivariate BrdUrd/PI labeling of DNA with flow cytometric analysis. Contour plots showing cells with and without BrdUrd labeling after 
one hour and six hours of BrdUrd incubation. Cells were pulsed with BrdUrd for one hour or six hours after treatment with or without PSP (25 μg/ml) 
for 72 hours. Cells at G0/G1 and G2/M are BrdUrd negative labeled. Most of the S-phase cells actively undergoing DNA synthesis were labeled with 
BrdUrd. The one hour BrdUrd-labeled cells progressed through G2/M phase; divided after six hours of BrdUrd labeling and reappeared in the G0/G1 
phase (6 hours BrdUrd labeled cells). These cells are called labeled divided cells (Ld) and the remaining S-phase cells are called labeled undivided cells 
(Lud). Values are expressed as mean (SD) (n = 5). * P < 0.05; ***P < 0.001, vs. control.
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phase cells.
The G2/M phase cells almost exclusively expressed
cyclin B1(Figure 10a). PSP treatment for 72 hours
increased the cyclin B1 level in G2/M phase by 58.44% (P
< 0.001) (Figure 10b). Western blot analysis later con-
firmed the up-regulation of cyclin B1 during the PSP
treatment (Figure 10c). Unlike cyclin E, the reduction of
cyclin B1 was only specific to G2/M and to the non-prolif-
erating cells. There was no cyclin B1 expression at the
pre-G1 peak (i.e. apoptotic cells), indicating that most of
the apoptotic cells in the pre-G1 peak came from the S-
phase.
Discussion
One of the advantages of PSP over many western antican-
cer drugs is its ability to distinguish cancer cells from the
normal cells [4-6]. Moreover, PSP can synchronize cells
and kill them in S-phase [5,6]. PSP is therefore a useful
anticancer agent against rapidly proliferating tumor cells
characterized by high proportion of S-phase cells exem-
plified by the HL-60 cells. The present study shows that
PSP-pretreated cells enhanced the cytotoxicity of CPT.
Exposure of HL-60 cells to PSP delayed cell progres-
sion, predominantly through S and with lesser extent
through G2. To a lesser degree, cells exiting G2/M were
also impaired, significantly reducing G1 cells after PSP
treatment. PSP increased the DNA content in HL-60 cells
(detected with BrdUrd labeling); however, the rate of
DNA synthesis was reduced (detected with [3H]-thymi-
dine uptake).
CPT is cytotoxic to human promyelocytic HL-60 cells
in both S and G2 phase [16]. Its increased toxicity towards
S-phase cells may be explained by the possible collision
between moving replication forks and CPT-stabilized
topoisomerase I-DNA cleavable complexes, resulting in
fork arrest and its breakage [17]. We previously reported
that PSP inhibited topoisomerase IIα in the HL-60 cells
[5]. It is not clear whether PSP exhibits similar effect as
CPT in terms of inhibiting the TOP1 activity. Further
studies are warranted to test such a possibility.
Figure 6 Effect of PSP, CPT and PSP+CPT treatments on HL-60 apoptosis. HL-60 cells were treated with PSP (25 μg/ml) for 72 hour before CPT (1 
μM) was added. CPT was added at 72 hours and samples were collected after five hours of incubation. Cells were identified and quantified using an-
nexin V/PI flow cytometric assay. R3 represents viable cells (PI-ve, annexin V-ve); R4 represents early apoptotic cells (PI-ve, annexin V+ve) and R2 rep-
resents late apoptotic cells (PI+ve, annexin V+ve). Values are expressed as means (SD) (n = 4). * P < 0.001, vs. CPT.
Figure 7 Annexin V/PI flow cytometric analysis of apoptotic pop-
ulation of HL-60 cells treated with PSP, CPT and PSP+CPT treat-
ments. HL-60 cells were incubated with or without PSP (25 μg/ml) for 
72 hours. The cells were subsequently exposed to CPT at concentra-
tions of 0, 10, 100 and 1000 nM for five hours. Apoptotic cells were 
identified and quantified with flow cytometry with annexin V/PI stain-
ing. Results are expressed as means (SD) of four individual experiments 
analyzed with Winlist software.
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inducing DNA fragmentation (pre-G1 peak) at higher
doses (100 μg/ml) [5]. The present study demonstrated
that PSP enhanced cytotoxicity or the sensitivity of the
HL-60 cells induced by CPT (detected with annexin V/PI
flow cytometry). Flow cytometry analysis showed that
PSP enhanced the anticancer effects of CPT via either cell
cycle perturbation at low dose or apoptotic machinery at
high dose. PSP at low dose (25 μg/ml) caused S-phase
accumulation, which may be up-regulated by the G1/S
checkpoint cyclin E. The pre-G1 population increased
with a significant decrease in S-phase population, sug-
gesting that PSP must first accumulate the S-phase cells
before exerting its cytotoxic effect on the HL-60 cells.
Our propose that the ability of PSP to arrest cancer cells
Table 1: The effect of CPT and CPT with PSP pretreatment on normal human peripheral blood mononuclear cells.
Treatment Viable cells Apoptotic cells Necrotic cells
Control 37.93 (5.75) 29.62 (1.87) 31.51 (5.00)
PSP (25 μg/ml) 39.33 (4.70) 28.26 (2.18) 31.49 (4.11)
CPT (1 μM) 34.91 (5.39) 30.95 (2.49) 33.33 (5.05)
PSP (25 μg/ml) + CPT (1 μM) 40.80 (9.26) 28.85 (4.51) 29.38 (6.52)
Normal human peripheral blood mononuclear cells were treated with PSP (25 μg/ml) for 72 hour prior to addition of CPT (1 μM). CPT was 
added at 72 hours and samples were collected after five hours of drug incubation. Cells were identified and quantified using Annexin V/PI 
flow cytometric assay. Values are expressed as mean (SD) (n = 8).
Figure 8 DNA flow cytometric analysis of apoptotic population and changes in cell cycle distribution of HL-60 cells. HL-60 cells were pre-
treated with or without PSP (25 μg/ml) for 72 hours. The cells were subsequently exposed to CPT (1 μM) for up to seven hours. A time profile of the 
Pre-G1 peak (A) and the changes of cell cycle distribution in G0/G1 (B), S (C) and G2/M (D) were identified and quantified with flow cytometry with PI 
staining. Results are expressed as means (SD) of four individual experiments analyzed with Winlist and Modfit software.
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cells to undergo apoptosis induced by CPT.
Study results indicated that cyclin E was more impor-
tant than cyclin B1 in CPT-induced apoptosis in the HL-
60 cells. Cyclin E is essential in the cell cycle from G1 to S-
phase and the initiation of DNA replication [18-21]. PSP-
induced cyclin E expression led to S-phase cell accumula-
tion, which subsequently delayed DNA synthesis, hence a
longer Ts in the PSP pre-treated HL-60 cells. In addition
to the regulatory role in G1-S transition, cyclin E may also
be involved in apoptosis. A recent study demonstrated
that the induction of cyclin E expression sensitized the
IM-9 cells to γ-irradiation-induced apoptosis [22]. Irradi-
ation-induced cyclin E overexpression could result in an
enhanced caspases activation and phosphatidylserine
translocation on the plasma membrane, leading to cell
death in the IM-9 cells [22]. Furthermore, DNA-damage-
induced cyclin E-H1K was suggested to be involved in a
late apoptosis checkpoint [23]. We believe that the up-
regulation of the cyclin E may be a sensitization process
of PSP whereby the HL-60 cells undergo DNA damage by
CPT. Consequently, a larger number of protein-associ-
ated DNA strand breaks may lead to more pronounced
apoptosis induction.
Conclusion
The present study shows that PSP extracted from Corio-
lus versicolor can increase the sensitization of the HL-60
cells to undergo effective apoptotic cell death induced by
CPT. The pattern of sensitivity of cancer cells is similar to
that of HL-60 cells. PSP rapidly arrests and/or kills cells in
S-phase and did not interfere with the anticancer action
of CPT. PSP is a potential adjuvant to treat human leuke-
mia as rapidly proliferating tumors is characterized by a
high proportion of S-phase cells.
Figure 9 Effect of PSP, CPT and PSP+CPT on cyclin E expression in HL-60 cells. (a) HL-60 cells were treated or pre-treated with PSP (25 μg/ml) for 
72 hour before CPT (1 μM) was added. CPT was added at 72 hours and samples were collected after five hours of incubation. (b) Cyclin E was expressed 
in non-PSP-treated cells (control) and PSP-treated HL-60 cells. Results are expressed as means (SD) of four individual experiments analyzed with Winlist 
and Modfit software. * P < 0.001, vs. non-PSP treated. (c) Western blot analysis of whole cell lysate of cyclin E expression in HL-60 cells with and without 
PSP treatment.
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